Clinical Trial Update: Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants [Phase 2]

View source ↗

Summary

Phase 2 feasibility trial of aerosolized lucinactant (Surfaxin) for prevention of respiratory distress syndrome in premature infants was terminated, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• SURFAXIN (lucinactant)

Snippet

Sponsor: Windtree Therapeutics | Conditions: Respiratory Distress Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2012-06-13